자궁근종 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 유형별, 치료별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The global uterine fibroids treatment market was valued at USD 4.74 billion in 2024 and is projected to reach USD 7.76 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.53% during the forecast period. This growth is primarily driven by the increasing prevalence of uterine fibroids among women of reproductive age. Uterine fibroids, non-cancerous tumors that develop in the uterus, affect a significant proportion of women worldwide, leading to symptoms such as heavy menstrual bleeding, pelvic pain, and reproductive complications. Rising awareness of fibroid-related health issues is encouraging more women to seek medical interventions, thereby increasing the demand for effective treatment options. Advancements in pharmaceuticals, innovations in minimally invasive procedures, and a growing preference for non-surgical treatments are reshaping the market dynamics. Additionally, the shift toward personalized medicine and targeted therapies is driving improved patient outcomes.

Key Market Drivers

Rising Prevalence of Uterine Fibroids

The rising incidence of uterine fibroids is a key driver of market growth. Uterine fibroids, benign growths in the uterus, have become increasingly common, especially among women, impacting their quality of life and reproductive health. Factors such as delayed childbearing, changing lifestyles, and obesity are contributing to the rise in fibroid diagnoses. According to the Centers for Disease Control and Prevention (CDC) in 2021, 14.6% of women aged 18 and older in the United States have undergone a hysterectomy, a common surgical treatment for uterine fibroids. As more women experience symptoms such as heavy menstrual bleeding, pelvic pain, and fertility issues, the demand for medical interventions is increasing.

This growing patient population represents a substantial market opportunity for healthcare providers, pharmaceutical companies, and medical device manufacturers. In response, there has been a surge in research and development, leading to innovative treatments such as minimally invasive surgeries, pharmaceutical interventions, and novel therapies targeting the molecular mechanisms of fibroid growth.

Additionally, the rise in uterine fibroid awareness campaigns, improved access to healthcare, and enhanced patient education have made it easier for women to seek timely medical care, further driving the demand for uterine fibroid treatments. As the incidence of uterine fibroids continues to grow, there is a pressing need for innovative and patient-centric solutions.

Key Market Challenges

Limited Non-Surgical Treatment Options

A major challenge facing the global uterine fibroids treatment market is the limited availability of non-surgical alternatives. While surgical interventions have traditionally been the primary treatment option, non-surgical treatments are becoming increasingly important for women who wish to preserve fertility, reduce risks, and minimize recovery times.

Current pharmaceutical treatments, such as GnRH agonists and selective progesterone receptor modulators (SPRMs), help alleviate symptoms and reduce fibroid size. However, they often come with side effects, including hot flashes, bone density loss, and mood swings, and may not offer long-term solutions since fibroids tend to regrow after treatment discontinuation.

Minimally invasive non-surgical procedures like uterine artery embolization (UAE) and focused ultrasound surgery (FUS) have gained popularity. UAE blocks blood flow to the fibroids, causing them to shrink, while FUS uses high-intensity ultrasound waves to destroy them. Though these treatments are less invasive, they are not suitable for all patients. For example, UAE may not be ideal for women planning to conceive, and FUS has limitations regarding the size and location of fibroids it can treat. Moreover, access to these procedures can be limited by cost and availability, particularly in regions with constrained healthcare resources.

Key Market Players

• Gynesonics Inc.
• Medtronic Plc.
• Boston Scientific Corporation
• Karl Storz GmbH
• Pfizer Inc.
• Abbvie Inc.
• Richard Wolf GmbH
• CooperSurgical Inc.
• Olympus Corporation
• Myovant Sciences GmbH

Report Scope

The global uterine fibroids treatment market is segmented as follows:

By Type:

• Subserosal Fibroids
• Intramural Fibroids
• Submucosal Fibroids
• Pedunculated Fibroids

By Treatment:

• Hormone Therapy
• Androgens
• Gonadotropin-Releasing Hormone Antagonists
• Uterine Artery Embolization
• Myomectomy
• Hysterectomy

By End-User:

• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

By Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia-Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

The report includes detailed company profiles of major players in the global uterine fibroids treatment market.

Available Customizations

TechSci Research offers the following customizations to the global uterine fibroids treatment market report:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Uterine Fibroids Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids, Pedunculated Fibroids)
  • 5.2.2. By Treatment (Hormone Therapy, Androgens, Gonadotropin-Releasing Hormone Antagonists, Uterine Artery Embolization, Myomectomy, Hysterectomy)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Uterine Fibroids Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Uterine Fibroids Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By End-User
  • 6.3.2. Mexico Uterine Fibroids Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By End-User
  • 6.3.3. Canada Uterine Fibroids Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By End-User

7. Europe Uterine Fibroids Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Uterine Fibroids Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By End-User
  • 7.3.2. Germany Uterine Fibroids Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Uterine Fibroids Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Uterine Fibroids Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Uterine Fibroids Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By End-User

8. Asia-Pacific Uterine Fibroids Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Uterine Fibroids Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Uterine Fibroids Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By End-User
  • 8.3.3. South Korea Uterine Fibroids Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By End-User
  • 8.3.4. Japan Uterine Fibroids Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Uterine Fibroids Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By End-User

9. South America Uterine Fibroids Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Uterine Fibroids Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By End-User
  • 9.3.2. Argentina Uterine Fibroids Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By End-User
  • 9.3.3. Colombia Uterine Fibroids Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By End-User

10. Middle East and Africa Uterine Fibroids Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Uterine Fibroids Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By End-User
  • 10.3.2. Saudi Arabia Uterine Fibroids Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By End-User
  • 10.3.3. UAE Uterine Fibroids Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Gynesonics Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Medtronic Plc.
• 14.3. Boston Scientific Corporation
• 14.4. Karl Storz Gmbh
• 14.5. Pfizer Inc.
• 14.6. Abbvie Inc.
• 14.7. Richard Wolf GmbH
• 14.8. CooperSurgical Inc.
• 14.9. Olympus Corporation
• 14.10. Myovant Sciences GmbH

15. Strategic Recommendations

16. About Us & Disclaimer